What long-term monitoring is required for patients with atrial fibrillation (Afib) (AF)?

Updated: Nov 18, 2019
  • Author: Lawrence Rosenthal, MD, PhD, FACC, FHRS; Chief Editor: Jeffrey N Rottman, MD  more...
  • Print

Assessment and reassessment of thromboembolic risk is necessary, and periodic ECG monitoring (especially when taking antiarrhythmic agents) and Holter monitoring are often necessary to assess for paroxysmal AF and/or rate control.


Experimental and clinical data suggest that renin-angiotensin system (RAS) antagonists and HMG-CoA reductase inhibitors (statins) may decrease the incidence of AF and increase the likelihood of successful cardioversion. [118, 119, 120, 121]

In addition, treatment of underlying cardiovascular risk factors such as hypertension, coronary artery disease (CAD), valvular heart disease, obesity, sleep apnea, diabetes, and heart failure is likely to decrease the incidence of AF. Fish oil preparations have also been shown to reduce ventricular arrhythmias in at-risk populations (CAD) and may also protect against AF.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!